Nuvectis Pharma, Inc.
Clinical trials sponsored by Nuvectis Pharma, Inc., explained in plain language.
-
New combo drug trial aims to fight resistant lung cancer
Disease control Recruiting nowThis early-stage trial is testing whether adding an experimental drug called NXP900 to an existing lung cancer medication (osimertinib) can help control advanced lung cancer that has started to grow again. It is for adults with a specific genetic change (EGFR mutation) whose canc…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for tough cancers: first human test of experimental drug begins
Disease control Recruiting nowThis is the first study in people to test a new drug called NXP900 for advanced solid tumors. The main goals are to find a safe dose and see how the body processes the drug. The study will also look for early signs that the drug can shrink tumors, especially in cancers with speci…
Phase: PHASE1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC